Overview
Noncommunicable diseases (NCDs) – which include diabetes, hypertension, cardiovascular disease, cancer and chronic respiratory disease - are the leading causes of morbidity and mortality globally. Available data demonstrates that nearly 80% of NCD deaths occur in low- and middle-income countries. By 2030, NCDs are expected to kill 52 million people per year worldwide, nearly five times more than communicable diseases.
The cumulative global cost of illness and lost production between 2011-2030, associated with diabetes, cardiovascular disease, cancer, chronic respiratory disease, and mental illness is projected to reach USD $47 trillion, equivalent to 5 percent of the world’s GDP in 2010. Non-communicable diseases (NCDs) account for over 65 percent of disease burden in the Asia-Pacific (APAC) region.
The incidence of NCDs increases with age, posing a challenge for rapidly aging populations across APAC. While the total population in the APAC region is expected to grow 20% by 2030, the prevalence of NCDs is projected to grow by over 40%.
Insurance represents a crucial source of protection and funding for healthcare costs (with 50 percent of costs associated with NCDs can be outpatient costs and a concern for insurers who pay domiciliary care).
Therefore, prudent underwriting and diligent claim assessment contributes to the sustainability of the overall insurance ecosystem (both life and health).
Diabetes Mellitus & Hypertension in Malaysia
Nearly 1 in 5 Malaysian adults, or 18.3% of the adult population has diabetes, says the Health Ministry. A recent survey showed that an estimated 3.9 million Malaysians aged 18 and above are suffering from diabetes (https://www.thestar.com.my/news/nation/2020/05/29/health-ministry-nearly-one-in-five-malaysians-has-diabetes)
Hypertension is one of the most common risk factors for cardiovascular disease and is also the leading cause of mortality globally. A study to assess the prevalence of hypertension and its associated risk factors among Malaysian population using data from the Malaysian Community Salt Study (MyCoSS) showed that hypertension is prevalent among adults in Malaysia. Those with older age, higher BMI, and/or diabetes are more likely to have hypertension. (https://jhpn.biomedcentral.com/articles/10.1186/s41043-021-00237-y )
This programme will target and offer deep insights into diabetes mellitus, hypertension and dyslipidaemia, that go hand in hand to cause a major NCD burden of insurance claims. Pathogenesis, diagnostic criteria, earliest markers, metabolic syndrome, acute and chronic complications and concept of target organ damage along with case histories will also be discussed.
Key Learning Outcome:
At the end of the course, participants will be able to:
- Better evaluate proposals w.r.t. cardiovascular metabolic diseases (hypertension, diabetes mellitus & dyslipidemia) and prognosticate terminal events - Underwriting professionals (both life and health insurance)
- Better evaluate proposals w.r.t. cardiovascular metabolic diseases (hypertension, diabetes mellitus & dyslipidemia) - Claims professionals (both life and health insurance)
-
Understand the interaction of the risk factors
Course Content:
-
Concept of Chronic Lifestyle ailments:
Why? How? and When?
-
Concept of Cardiovascular Metabolic
Diseases (CVMD)
-
Concept of Chronic Silent Killers
-
Causative Risk Factor for Chronic Diseases
-
Definitions (DM, HTN, Dyslipidaemia,)
-
Metabolic Syndrome
-
Diabetic Dyslipidaemia
-
Glucose Metabolism Progression to Diabetes
-
Understanding HTN
-
Understanding Lipid Metabolism
Diabetes
- Classification
- Current Diagnostic Criteria and Screening
- Prediabetes
- Acute Complications of Diabetes
- Chronic Complications of Diabetes
- Diabetes + HTN
- Diabetes Nephropathy
- Diabetic Eye Disease
- Infections in a Diabetic (immunocompromised state)
- Diabetic Foot
- Nutrition to Manage CVMD
- Exercises to Manage CVMD
Target Audience
- Life, Health and Critical Illness Underwriters
-
Claims personnel in Life, Health & Critical Illness
Speaker Profile
Dr C H Asrani
DNB (Family medicine); PGD Medicolegal Systems; Adv. Dip in Forensic Medicine & Toxicology
CEO, Founder – INCHES’ group of companies
Dr C H Asrani has over four decades of active clinical practice and over two decades of experience in insurance consulting and training insurance professionals (underwriting and claims for both life and health insurance).
A renowned expert in this area, Dr Asrani pioneered medical audit in insurance in India. With over 300 presentations in insurance risk management, Dr Asrani has been conducting training across Dubai, Bangkok, Kuala Lumpur and Singapore. He also has the distinction of being associated with the National Health Authority (Ayushman Bharat scheme), consulting with The World Bank and being a panelist on various talks on monitoring, audit, and fraud surveillance in the Insurance industry. He is also one of the first medico entrepreneur to devise cloud-based fraud prevention solutions for insurance companies in India (www.inches-insuretech.com/).
He is now on an expansion drive to extend his company’s service innovative solutions internationally. The solutions include medical insights for underwriting, rational claim adjudication, medical processes architecture, clinical audit of claims & underwriter or claim assessor trainings. Dr Asrani’s group of companies have also developed Intelli-Claims, a proprietary tool for medical adjudication of claims using standard treatment guidelines and rule-based analytics.
Date and Time
Date: 23 - 24 February 2022
Time: 9.30 a.m. - 12.30 p.m.
Registration Closing Date: 16 February 2022
Price
Early Bird (Register before 9 February 2021)
MII Member:
RM 550 (single), RM 500 (Group)
Non Member:
RM 750 (Single), RM 700 (Group)
International:
USD200 (Single), USD180 (Group)
Normal Fee
MII Member:
RM 650 (single), RM 600 (Group)
Non Member:
RM 850 (Single), RM 800(Group)
International:
USD220 (Single), USD200 (Group)
|
